Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy
Key Points
-
Datopotamab deruxtecan (Dato-DXd) received priority review after promising data from the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials.
-
Patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC) may soon have a new treatment option.
-
Dato-DXd adverse effects can affect quality of life.
At the American Society of Clinical Oncology (ASCO) Annual Meeting, Narjust Florez, MD, FASCO, of Dana-Farber Cancer Institute, weighed in on the potential FDA approval of Dato-DXd for previously treated advanced EGFR-mutated NSCLC. She discussed trial findings of the antibody-drug conjugate (ADC) with Coral Olazagasti, MD, of the University of Miami Health System. “We have to remember that it’s about patient selection for dato,” Dr. Florez said.
Although the ADC shows promising tumor responses, it also comes with significant toxicities, such as mouth ulcers and hair loss, that can affect a patient’s quality of life.
Earlier this year, the FDA granted priority review for Dato-DXd treatment in adult patients with locally advanced or metastatic EGFR-mutated NSCLC based on data from the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials. In these trials, Dato-DXd demonstrated a confirmed objective response rate of 42.7% as assessed by blinded independent central review and a median duration of response of 7 months.